hlx26
mAbexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 30, 2021 (NCT05078593)
Timeline
Indications
Mechanism of action
- LAG3ANTAGONIST
LAG3
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05787613 | Phase 2 | Jul 10, 2023 | Shanghai Henlius Biotech |
| NCT05584137 | Phase 2 | Nov 22, 2022 | Shanghai Henlius Biotech |
| NCT05400265 | Phase 1 | Jul 26, 2022 | Shanghai Henlius Biotech |
| NCT05078593 | Phase 1 | Aug 30, 2021 | Shanghai Henlius Biotech |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shanghai Henlius Biotech | For profit | 4 | 4 | 2 | 2021 |
1 organizations
Page 1 / 1